Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.
Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.
Alternative to sodium bicarbonate for metabolic acidosis when lactate metabolism is intact,Fluid and electrolyte replenishment,Mild to moderate metabolic acidosis
FDA-approved: For intravenous administration as a source of water, electrolytes, and calories in patients requiring fluid and electrolyte replacement.,Off-label: Not typically used off-label; primarily for maintenance or replacement therapy.
Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.
Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.
30–60 minutes for lactate conversion; bicarbonate component determined by CO2 excretion.
Not applicable; components are endogenous substances. Dextrose half-life ~15-20 min after infusion; electrolytes distribute and are cleared renally with half-lives dependent on renal function.
Primarily hepatic gluconeogenesis; lactate is converted to glucose via the Cori cycle, or oxidized to carbon dioxide and water; metabolism requires adequate liver function.
Dextrose undergoes glycolysis and the citric acid cycle; electrolytes are not metabolized but are excreted or incorporated into body pools.
Primarily renal as bicarbonate and lactate; <5% unchanged.
ISOLYTE E in Dextrose 5% is a balanced electrolyte solution with glucose. Electrolytes are primarily excreted renally; water and dextrose are metabolized. Biliary/fecal excretion is negligible. Dextrose is metabolized to CO2 and water.
Negligible (<1%); does not bind significantly to plasma proteins.
None for electrolytes and dextrose; sodium, potassium, chloride, magnesium, acetate, and gluconate are free ions in solution.
0.4-0.6 L/kg; distributes primarily in extracellular fluid.
Sodium and chloride distribute primarily in extracellular fluid (~0.2 L/kg). Dextrose distributes in total body water (~0.6 L/kg). Potassium distributes in intracellular fluid (~0.6 L/kg after equilibration).
Intravenous: 100%
100% intravenous; not administered by other routes.
Contraindicated in severe renal dysfunction (e GFR < 30 m L/min/1.73 m²) due to risk of hypernatremia and volume overload. In patients with e GFR 30-59 m L/min/1.73 m², use with caution, reduce infusion rate by 25-50%, and monitor serum sodium and fluid balance closely.
In renal impairment (e GFR < 30 m L/min/1.73m²), reduce total volume to 500-1000 m L/day with careful monitoring of potassium, sodium, and glucose; avoid if hyperkalemia or fluid overload.
Contraindicated in severe hepatic impairment (Child-Pugh Class C) due to impaired lactate metabolism. In Child-Pugh Class A or B, use with caution, reduce infusion rate by 50%, and monitor arterial blood gases and lactate levels frequently.
No specific dose adjustment for Child-Pugh class; monitor for fluid overload and electrolyte imbalances; in severe hepatic impairment, reduce volume to 500-1000 m L/day.
Intravenous infusion: Administer 3-5 m L/kg of 1/6 Molar sodium lactate as a bolus over 30 minutes, followed by a continuous infusion at 0.5-1 m L/kg/hour, titrated to correct metabolic acidosis. Maximum infusion rate: 2 m L/kg/hour.
Weight-based: 20-50 m L/kg/day for maintenance; neonates and infants: 100-150 m L/kg/day; adjust based on glucose, electrolytes, and hydration status; maximum rate 4 m L/kg/hour for neonates.
Use with caution due to decreased renal function and higher risk of fluid overload. Start at lower end of dosing range (0.5-1 m L/kg/hour) and monitor serum electrolytes, fluid balance, and renal function closely. Contraindicated if e GFR < 30 m L/min/1.73 m².
Start with lower volumes (500-1000 m L/day) due to decreased renal function and risk of fluid overload; monitor serum electrolytes, glucose, and central venous pressure.
None.
Not applicable; no FDA boxed warning exists for this product.
Use with caution in patients with impaired liver function, lactic acidosis, or conditions predisposing to lactic acidosis (e.g., shock, hypoxia). Monitor serum electrolytes and acid-base status. Risk of hyperlactatemia if metabolism is impaired.
Monitor serum electrolytes, fluid balance, and glucose levels; avoid fluid overload in patients with cardiac or renal impairment; risk of hyperglycemia in diabetic patients; use with caution in patients with metabolic alkalosis or hypokalemia.
Severe lactic acidosis, hyperlactatemia, severe hepatic impairment, metabolic alkalosis, hypocalcemia, and patients with known hypersensitivity to sodium lactate.
Hypersensitivity to any component; clinically significant hyperglycemia; severe metabolic acidosis; hyperkalemia (for potassium-containing formulations); hypermagnesemia; fluid overload conditions.
No specific food interactions known. However, patients on sodium-restricted diets should account for the sodium content of this solution (approximately 167 m Eq/L).
No specific food interactions known. Monitor electrolyte intake in patients with electrolyte imbalances.
Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, but no specific fetal risks are associated with maternal administration of this physiologic compound.
ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies have not been conducted. Dextrose and electrolytes are considered essential nutrients and are generally safe when used as indicated. However, administration during labor and delivery may cause fluid and electrolyte imbalances. First trimester risks are theoretical; second and third trimesters may involve risks of maternal hyperglycemia and fetal hyperinsulinemia if dextrose infusion is excessive. No specific teratogenicity reported.
Sodium lactate is a normal constituent of breast milk. Exogenous administration is unlikely to significantly alter milk levels. M/P ratio not established. Considered compatible with breastfeeding.
Dextrose and electrolytes are normal constituents of human milk. Following intravenous administration, concentrations in milk are expected to parallel maternal plasma levels. No specific M/P ratio is available. Use during breastfeeding is considered compatible; however, monitor for adverse effects in the infant such as electrolyte imbalance or hyperglycemia if maternal infusion is prolonged or high volume.
No dose adjustment required. Physiologic increases in plasma volume during pregnancy may dilute infused fluids, but standard dosing based on clinical status is appropriate.
Pregnancy induces increased plasma volume and glomerular filtration rate, potentially diluting electrolytes and altering glucose metabolism. Dose adjustments may be required: consider lower dextrose infusion rates to avoid maternal hyperglycemia and fetal hyperinsulinemia. Monitor electrolytes closely; adjust potassium and magnesium supplementation as needed. No specific dose adjustment is universally recommended; individualize based on maternal weight, clinical status, and monitoring results.
Sodium lactate 1/6 Molar is a crystalloid solution providing approximately 167 m Eq/L of sodium and 167 m Eq/L of lactate. It is metabolized to bicarbonate in the liver, making it useful for correcting metabolic acidosis, especially in patients with lactic acidosis or those unable to tolerate bicarbonate due to hypocalcemia or hypercapnia. Monitor serum electrolytes, lactate levels, and acid-base status. Avoid in severe liver dysfunction as conversion to bicarbonate is impaired. Use with caution in patients with heart failure or renal impairment due to sodium load. For intravenous use only; do not administer with calcium-containing solutions due to precipitation risk.
ISOLYTE E in DEXTROSE 5% is an isotonic crystalloid solution for IV administration. Contains electrolytes (Na, K, Mg, Cl, acetate, gluconate) and dextrose 5%. Use with caution in patients with renal impairment, heart failure, or hyperkalemia. Monitor serum electrolytes, blood glucose, and fluid balance. Not for use as a sole source of nutrition. Do not administer if solution is discolored or contains particulates.
This medication is a solution that helps correct acid buildup in your blood.,It will be given through a vein (intravenously) by a healthcare professional.,You may need frequent blood tests to monitor your electrolyte levels and acid-base balance.,Inform your doctor if you have liver disease, heart failure, or kidney problems.,Report any signs of fluid overload such as shortness of breath, swelling in the ankles or legs.,Do not take any other medications or supplements without consulting your doctor.,This solution contains sodium; discuss any dietary sodium restrictions with your healthcare provider.
Inform your healthcare provider about all medical conditions, especially kidney disease, heart failure, or diabetes.,Report any signs of allergic reaction such as rash, itching, or trouble breathing.,Tell your doctor if you experience swelling, shortness of breath, or irregular heartbeat.,This solution contains dextrose (sugar); monitor blood glucose if you have diabetes.,Do not use if the bag is damaged or solution is cloudy.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER vs ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER, answered by our medical review team.
SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is a Electrolyte Solution that works by Sodium lactate is a source of bicarbonate precursor. It is metabolized to bicarbonate in the liver, which buffers metabolic acidosis, restoring acid-base balance.. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is a Intravenous Electrolyte Solution with Dextrose that works by Isolyte E in Dextrose 5% provides fluid, electrolytes, and calories. Dextrose is metabolized to carbon dioxide and water, yielding energy. Electrolytes (sodium, potassium, magnesium, chloride, acetate, gluconate) maintain acid-base balance and osmotic pressure.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is: Intravenous infusion: The typical adult dose is 300-500 m L of 1/6 Molar sodium lactate solution (approximately 167 m Eq/L each of sodium and lactate, 1 L contains 167 m Eq of sodium and lactate) administered as a continuous intravenous infusion at a rate of 0.5-2.5 m L/kg/hour, adjusted based on the severity of acidosis and clinical response. Maximum infusion rate: 2.5 m L/kg/hour.. The standard adult dose of ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is: Intravenous infusion; typical adult dose is 1000-2000 m L per day (30 m L/kg/day) adjusted for fluid and electrolyte needs; rate based on clinical status.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER and ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. SODIUM LACTATE 1/6 MOLAR IN PLASTIC CONTAINER is classified as Category C. Sodium lactate is a normal metabolic intermediate and component of IV fluids. No teratogenic effects are known at therapeutic doses. Risk cannot be ruled out in first trimester, bu. ISOLYTE E IN DEXTROSE 5% IN PLASTIC CONTAINER is classified as Category C. ISOLYTE E in Dextrose 5% is an intravenous electrolyte and carbohydrate solution. There are no adequate and well-controlled studies in pregnant women. Animal reproduction studies h. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.